Bioavailability of Calcitriol After Oral, Intravenous and Intraperitioneal Doses in Dialysis Patients.

Salusky, I. B.; Goodman, William G.; Norris, Keith C.; Horst, Ronald L.; Fine, Richard Ν.; Jw, Coburn

doi:10.1515/9783110846713.783

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perhaps for the same reason that intermittent intravenous calcitriol appears to work in patients refractory to o r a l c a l c i t r i o l : m a r k e d l y e l e v a t e d 1,25dihydroxyvitamin D levels can be achieved which presumably better saturate 1,25-dihydroxyvitamin D receptors on parathyroid cells and cause regres- dihydroxyvitamin D to a peak of 100 pg/ml at 8 hr, while a comparable intravenous dose increased 1,25-dihydroxyvitamin D levels to 450 pg/ml within 15 min of the injection followed by a decrease to 150 pg/ml at 30 min and 100 pg/ml at 8 hr (10). Similar results were observed in adolescent dialysis patients who were tested with oral and intravenous calcitriol (15).…”

supporting

confidence: 80%

Pulse Calcitriol Therapy

Andress

1993

Seminars in Dialysis

View full text Add to dashboard Cite

supporting

confidence: 80%

Pulse Calcitriol Therapy

Andress

1993

Seminars in Dialysis

View full text Add to dashboard Cite

“…Over the last decade, several studies have documented the efficacy of intermittent calcitriol therapy in the management of secondary hyperparathyroidism both in children and in adults treated with dialysis [34,36,37,38,39]. Despite the greater bioavailability of intravenous calcitriol [40], prospective studies show that intermittent oral calcitriol was as equally effective as intermittent intravenous calcitriol in reducing serum PTH levels in adult patients treated with hemodialysis [36,37]. During intermittent oral and intravenous calcitriol therapy, the degree of reduction of bone formation rate appears to be greater than PTH levels [38,41].…”

Section: Calcitriol Therapy In Renal Failurementioning

confidence: 99%

Are new vitamin D analogues in renal bone disease superior to calcitriol?

Salusky

2005

Pediatr Nephrol

View full text Add to dashboard Cite

Progression of chronic kidney disease is associated with an early reduction in serum calcitriol levels; thus, therapy with calcitriol should be initiated early in the course of chronic kidney disease to prevent the development of secondary hyperparathyroidism. Initial studies demonstrated a potential role of calcitriol in the prevention of growth retardation in children with chronic kidney disease prior to dialysis. But the optimal parathyroid hormone (PTH) levels that will maximize growth response during calcitriol treatment remain to be defined. Therapy with calcitriol has been shown to control the biochemical and skeletal manifestations of secondary hyperparathyroidism, but patients developed hypercalcemia, hyperphosphatemia and adynamic osteodystrophy. Thus, new vitamin D analogues with a lower hypercalcemic response have been developed. Although comparative studies are lacking, current evidence indicates that these new active vitamin D sterols (19-nor-paracalcitol and doxercalciferol) adequately control secondary hyperparathyroidism with minimal changes in serum calcium and phosphorus levels during treatment with calcium-containing binders. The long-term effect of such therapies on the skeleton and the process of vascular calcifications remain to be evaluated.

show abstract

Losses of Calcitriol to Peritoneal Dialysis Bags and Tubing

Vieth

Ledermann

et al. 1989

Perit Dial Int

View full text Add to dashboard Cite

Peritoneal dialysis provides a convenient means of administering calcitriol. We investigated in vitro the efficiency with which this approach would deliver the drug to patients. We used an injectable preparation of calcitriol, Calcijex® (Abbott Laboratories, Montreal, Quebec, Canada), which we radiolabelled by adding radioactive 1,25 dihydroxyvitamin D3 to it. The preparation was injected into dialysis bags and drained through appropriate tubing to monitor delivery of the radiolabelled calcitriol. By 2 h after injecting calcitriol into dialysis bags, 50% of the dose was left in the fluid, by 20 h only 26% was left. The delivered drug was pure 1,25-dihydroxyvitamin D3 based on chromatographic analysis of the recovered radiochemical. To study what would happen if the drug was in the bag for a minimal length of time the calcitriol was injected immediately prior to draining the fluid. We recovered 62.9% ± 5.2% SD of the dose from the tubing which would theoretically have entered a patient. There was no significant change in calcitriol dose delivered if the fluid was warmed to 37°C prior to injecting the drug and immediate drainage of the bag.

show abstract

Bioavailability of Calcitriol After Oral, Intravenous and Intraperitioneal Doses in Dialysis Patients.

Cited by 3 publications

References 0 publications

Pulse Calcitriol Therapy

Pulse Calcitriol Therapy

Are new vitamin D analogues in renal bone disease superior to calcitriol?

Losses of Calcitriol to Peritoneal Dialysis Bags and Tubing

Contact Info

Product

Resources

About